Trust Co. of Oklahoma lifted its holdings in Pfizer Inc. (NYSE:PFE) by 4.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 7,079 shares of the biopharmaceutical company’s stock after purchasing an additional 300 shares during the period. Trust Co. of Oklahoma’s holdings in Pfizer were worth $309,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Home Federal Bank of Tennessee raised its stake in shares of Pfizer by 0.8% during the 4th quarter. Home Federal Bank of Tennessee now owns 29,695 shares of the biopharmaceutical company’s stock worth $1,297,000 after acquiring an additional 249 shares in the last quarter. Advocacy Wealth Management Services LLC raised its stake in shares of Pfizer by 48.2% during the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 258 shares in the last quarter. Viridian Ria LLC raised its stake in shares of Pfizer by 0.9% during the 4th quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock worth $1,327,000 after acquiring an additional 280 shares in the last quarter. Capital City Trust Co. FL raised its stake in shares of Pfizer by 6.9% during the 4th quarter. Capital City Trust Co. FL now owns 5,139 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 330 shares in the last quarter. Finally, Legacy Financial Advisors Inc. raised its stake in shares of Pfizer by 5.5% during the 4th quarter. Legacy Financial Advisors Inc. now owns 6,593 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 343 shares in the last quarter. 69.49% of the stock is owned by hedge funds and other institutional investors.

Several research firms recently commented on PFE. Cantor Fitzgerald set a $53.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Sunday, December 30th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Thursday, January 31st. Zacks Investment Research lowered shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Credit Suisse Group restated a “neutral” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, January 28th. Finally, Bank of America upped their price target on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and seven have assigned a buy rating to the company. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $45.61.

In other news, EVP Douglas M. Lankler sold 38,800 shares of the stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $41.19, for a total value of $1,598,172.00. Following the sale, the executive vice president now owns 83,592 shares in the company, valued at $3,443,154.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mikael Dolsten sold 149,553 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $43.55, for a total transaction of $6,513,033.15. Following the completion of the sale, the insider now owns 390,097 shares in the company, valued at approximately $16,988,724.35. The disclosure for this sale can be found here. Insiders sold 332,526 shares of company stock worth $14,346,539 in the last quarter. Company insiders own 0.09% of the company’s stock.

Shares of Pfizer stock opened at $39.38 on Friday. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52. Pfizer Inc. has a 12-month low of $34.37 and a 12-month high of $46.47. The company has a market cap of $234.42 billion, a price-to-earnings ratio of 13.13, a P/E/G ratio of 2.37 and a beta of 0.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.01. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. The business had revenue of $13.98 billion for the quarter, compared to analyst estimates of $13.92 billion. During the same quarter in the prior year, the business posted $0.62 EPS. Pfizer’s revenue for the quarter was up 2.0% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.86 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Trust Co. of Oklahoma Increases Stake in Pfizer Inc. (PFE)” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/trust-co-of-oklahoma-increases-stake-in-pfizer-inc-pfe/2979156.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: What is a Real Estate Investment Trust (REIT)?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.